{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:27Z","timestamp":1786715127083,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0253-7613.190725","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T08:18:14Z","timestamp":1474273094000},"page":"509","source":"Crossref","is-referenced-by-count":2,"title":["Adverse drug reaction profile of microtubule-damaging antineoplastic drugs: A focused pharmacovigilance study in India"],"prefix":"10.4103","volume":"48","author":[{"given":"HasithaDiana","family":"Manohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Adiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajitha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.190725-1","first-page":"333","volume-title":"Challenges in pharmacovigilance","author":"Dikshit","year":"2010","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.190725-2","unstructured":"PvPI-Indian Pharmacopoeia Commission. Available from: http:\/\/www.ipc.gov.in\/PvPI\/ADRReportingForm.pdf. [Last accessed on 2016 Jun 19]."},{"key":"key-10.4103\/0253-7613.190725-3","first-page":"239","volume-title":"A method for estimating the probability of adverse drug reactions","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0253-7613.190725-4","unstructured":"World Health Organisation. Uppsala Monitoring Center. Causality Assessment of Suspected Adverse Reactions. Available from: http:\/\/www.who-umc.org\/Graphics\/24734.pdf. [Last accessed on 2016 Jun 19]."},{"key":"key-10.4103\/0253-7613.190725-5","first-page":"538","volume-title":"Focusing on the preventability of adverse drug reactions","author":"Schumock","year":"1992","journal-title":"Hosp Pharm"},{"key":"key-10.4103\/0253-7613.190725-6","first-page":"2229","volume-title":"Preventability and severity assessment in reporting adverse drug reactions","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"key-10.4103\/0253-7613.190725-7","unstructured":"World Health Organisation. Uppsala Monitoring Center. VigiFlow. Available from: http:\/\/www.who-umc.org\/DynPage.aspx?id=97223&mn1=7347&mn2=7252&mn3=7254. [Last accessed on 2016 Jun 19]."},{"key":"key-10.4103\/0253-7613.190725-8","unstructured":"World Health Organization. Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions: Why Health Professionals Need to Take Action; 2002. Available from: http:\/\/www.apps.who.int\/iris\/handle\/10665\/67378. [Last accessed on 2016 Jun 19]."},{"key":"key-10.4103\/0253-7613.190725-9","first-page":"1200","volume-title":"Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"key-10.4103\/0253-7613.190725-10","first-page":"619","volume-title":"Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine","author":"Boyette-Davis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.4103\/0253-7613.190725-11","first-page":"371","volume-title":"Update on taxane development: New analogs and new formulations","author":"Yared","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/0253-7613.190725-12","first-page":"1558","volume-title":"Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies","author":"Ehrhardt","year":"2013","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/0253-7613.190725-13","first-page":"124","volume-title":"Setting standards for proactive pharmacovigilance in India: The way forward","author":"Biswas","year":"2007","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.190725-14","first-page":"40","volume-title":"Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study","author":"Surendiran","year":"2010","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.190725-15","doi-asserted-by":"crossref","unstructured":"Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29-34.","DOI":"10.1001\/jama.1995.03530010043033"},{"key":"key-10.4103\/0253-7613.190725-16","first-page":"1285","volume-title":"Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation","author":"Astolfi","year":"2013","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0253-7613.190725-17","first-page":"303","volume-title":"A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital","author":"Shamna","year":"2014","journal-title":"Saudi Pharm J"},{"key":"key-10.4103\/0253-7613.190725-18","unstructured":"Hanlon JT, Ruby CM, Artz M. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy a Pathophysiologic Approach. 7 th ed. New York: McGraw Hill Inc.; 2008. p. 79-89."},{"key":"key-10.4103\/0253-7613.190725-19","unstructured":"Chabner BA. General principles of cancer chemotherapy. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman\u2032s the Pharmacological Basis of Therapeutics. 12 th ed. New York: McGraw Hill Inc.; 2011. p. 1667-75."},{"key":"key-10.4103\/0253-7613.190725-20","first-page":"626","volume-title":"The ten most common adverse drug reactions (ADRs) in oncology patients: Do they matter to you?","author":"Lau","year":"2004","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0253-7613.190725-21","first-page":"361","volume-title":"Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice","author":"Wickham","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"key-10.4103\/0253-7613.190725-22","first-page":"289","volume-title":"Incidence and preventability of adverse drug events in hospitalized adults","author":"Bates","year":"1993","journal-title":"J Gen Intern Med"},{"key":"key-10.4103\/0253-7613.190725-23","unstructured":"Suthar JV, Desai SV. A study of adverse cutaneous drug reactions in outdoor patients attending to Skin and V.D. Department of Shree Krishna Hospital, Karamsad. Int J Res Pharm Biomed Sci 2011;2:2229-3701."},{"key":"key-10.4103\/0253-7613.190725-24","unstructured":"Epidemiology of Hypersensitivity Drug Reactions\u202f: Current Opinion in Allergy and Clinical Immunology. Available from: http:\/\/www.journals.lww.com\/co-allergy\/Fulltext\/2005\/08000\/Epidemiology_of_hypersensitivity_drug_reactions. 2.aspx. [Last accessed on 2016 Jun 19]."},{"key":"key-10.4103\/0253-7613.190725-25","first-page":"81","volume-title":"Adverse drug reactions in Nigerian children","author":"Oshikoya","year":"2007","journal-title":"Paediatr Perinat Drug Ther"},{"key":"key-10.4103\/0253-7613.190725-26","first-page":"277","volume-title":"A study of adverse drug reactions in pediatric patients","author":"Priyadharsini","year":"2011","journal-title":"J Pharmacol Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"key-10.4103\/0253-7613.190725-27","first-page":"257","volume-title":"A prospective study of adverse drug reactions to artemisinin-based combination therapy in a tertiary care hospital in India","author":"Belhekar","year":"2012","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:20Z","timestamp":1786713920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.190725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["190725"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.190725","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}